- Raised $25M Series A led by Bessemer Venture Partners, Jan 2026
- Raised $5.5M Seed round led by TLV Partners, Nov 2024
- Raised $2.5M grant led by Gates Foundation, Jun 2026
About
Converge Bio is on a mission to empower biotech and pharmaceutical companies with Generative AI solutions to discover more effective drugs faster. The company trains Generative AI models on the core biological languages of DNA, RNA, and protein sequences and builds experimentally validated solutions around these models that any scientist can use. Their ultimate goal is to provide a dedicated AI solution to support scientists at any given stage of the drug discovery life cycle. To date, they have rolled out systems supporting target discovery, antibody design, protein manufacturing optimization, and biomarker discovery to their customer base. Converge Bio is a Tel Aviv and Boston-based technology company. The company operates on a tailored software-as-a-service model and has completed over 40 distinct development programs for more than 12 active clients.
Funding history · 3 rounds · $33.0M total
Offices
Q&A
- What is Converge Bio's primary focus?
- Converge Bio is developing a Generative AI platform for DNA, RNA, and protein sequences to revolutionize biological R&D.
- When was Converge Bio founded?
- Converge Bio was founded in May 2024.
- What was Converge Bio's most recent funding round?
- In June 2026, Converge Bio secured a Grant round of $2.5 million from the Bill & Melinda Gates Foundation.
- Which investors participated in Converge Bio's Series A round?
- In January 2026, Bessemer Venture Partners led Converge Bio's Series A round of $25 million.
- How many employees does Converge Bio currently have?
- Converge Bio has 11-50 employees.
- Who are the co-founders of Converge Bio?
- The co-founders of Converge Bio are Oded Kalev, who serves as CTO, and Dov Gertz, who serves as CEO.
- What product did Converge Bio use to improve cancer treatment?
- In May 2026, Converge Bio used its product ConvergeAB to improve a popular cancer treatment with a single prompt.
- What was the purpose of the $2.5M grant secured by Converge Bio in June 2026?
- The $2.5M grant secured by Converge Bio in June 2026 is intended to expand its fast-track AI gene discovery capabilities from pharmaceuticals to growing climate-resilient crops.
Team · 6
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | converge-bio.com |
|---|---|
| linkedin.com/company/102539353 |
Identifiers & details
| Legal name | CONVERGE BIO LTD |
|---|---|
| Founded | 2024-5 |
| Employees (exact) | 40 |
Radar intelligence
Web history (Wayback)
| Domain | converge-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516949781 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2024-03-04 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | פריש דניאל 3 תל אביב - יפו |